Swiss National Bank
MRNA icon

Swiss National Bank’s Moderna MRNA Stock Holding History

Swiss National Bank’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.6M Sell
679,900
-16,200
-2% -$838K 0.02% 459
2026
Q1 		$35.4M Buy
696,100
+3,000
+0.4% +$140K 0.02% 525
2025
Q4 		$20.4M Buy
693,100
+18,200
+3% +$494K 0.01% 656
2025
Q3 		$17.4M Buy
674,900
+11,200
+2% +$312K 0.01% 698
2025
Q2 		$18.3M Sell
663,700
-258,800
-28% -$6.82M 0.01% 651
2025
Q1 		$26.2M Sell
922,500
-500
-0.1% -$17.7K 0.02% 559
2024
Q4 		$38.4M Sell
923,000
-43,800
-5% -$2.09M 0.03% 490
2024
Q3 		$64.6M Buy
966,800
+3,200
+0.3% +$294K 0.04% 363
2024
Q2 		$114M Sell
963,600
-7,000
-0.7% -$886K 0.08% 217
2024
Q1 		$103M Sell
970,600
-41,000
-4% -$4.13M 0.07% 250
2023
Q4 		$101M Sell
1,011,600
-30,700
-3% -$2.58M 0.07% 254
2023
Q3 		$108M Sell
1,042,300
-141,700
-12% -$15.8M 0.08% 227
2023
Q2 		$144M Sell
1,184,000
-112,000
-9% -$14.9M 0.1% 193
2023
Q1 		$199M Sell
1,296,000
-55,400
-4% -$9.14M 0.14% 134
2022
Q4 		$243M Sell
1,351,400
-113,800
-8% -$18.6M 0.17% 111
2022
Q3 		$173M Sell
1,465,200
-20,300
-1% -$3.08M 0.12% 152
2022
Q2 		$212M Sell
1,485,500
-7,200
-0.5% -$1.03M 0.14% 130
2022
Q1 		$257M Buy
1,492,700
+188,600
+14% +$31.8M 0.15% 126
2021
Q4 		$331M Sell
1,304,100
-45,400
-3% -$13.3M 0.2% 90
2021
Q3 		$519M Buy
1,349,500
+58,600
+5% +$21.6M 0.33% 55
2021
Q2 		$303M Buy
1,290,900
+144,800
+13% +$25.9M 0.19% 97
2021
Q1 		$150M Buy
1,146,100
+103,200
+10% +$15M 0.1% 194
2020
Q4 		$109M Sell
1,042,900
-16,500
-2% -$1.67M 0.08% 262
2020
Q3 		$75M Buy
1,059,400
+28,500
+3% +$1.99M 0.06% 315
2020
Q2 		$66.2M Buy
+1,030,900
New +$56.5M 0.06% 331

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Swiss National Bank's MRNA Position: Q2 2026 in Review

Swiss National Bank reduced its Moderna (MRNA) stake by 2.3% in Q2 2026, selling an estimated $838K and leaving 679,900 shares worth $47.6M. The position accounts for 0.02% of the portfolio, ranked #459.

Swiss National Bank first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $519M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Swiss National Bank held 679,900 shares of Moderna worth $47.6M as of Q2 2026.
  • Swiss National Bank sold 16,200 Moderna shares in Q2 2026, an estimated $838K.
  • Moderna made up 0.02% of Swiss National Bank's portfolio in Q2 2026, its #459 holding.
  • Swiss National Bank first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Swiss National Bank's Moderna position peaked at $519M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.